BioPharmSignal logoBioPharmSignal

Biotech News

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Aligos Therapeutics (ALGS)Aligos TherapeuticsClinical readout

ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activation Single and multiple ascending doses planned Study will allow rapid advancement into participants with chronic HBV infection in Q4 2026 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos

Related news

ALGSAligos Therapeutics2026-07-13 12:00 EST

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

ALGSAligos Therapeutics2026-05-27 06:30 EST

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

NAMSNewAmsterdam Pharma2026-09-29 12:00 EST

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

MISTMilestone Pharmaceuticals Inc.2026-09-24 12:00 EST

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

MLYSMineralys Therapeutics2026-05-30 15:15 EST

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

VKTXViking Therapeutics2026-09-22 11:05 EST

Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

VKTXViking Therapeutics2026-06-24 11:05 EST

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

MLYSMineralys Therapeutics2026-05-18 20:05 EST

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

MNKDMannKind2026-06-03 10:05 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

SGMTSagimet Biosciences2026-09-30 10:00 EST

Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026

View all latest news

Aligos Therapeutics

Liver and Viral Diseases Aligos Therapeutics develops small-molecule and oligonucleotide therapies for liver and viral diseases. Its lead clinical effort targets chronic hepatitis B through suppression of viral antigen production. Pevifoscorvir Sodium Pevifoscorvir sodium is an antisense oligonucleotide designed to reduce hepatitis B...

Recent company news

ALGSAligos Therapeutics2026-10-05 20:05 EST

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

ALGSAligos Therapeutics2026-09-02 12:00 EST

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

ALGSAligos Therapeutics2026-09-02 12:00 EST

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

ALGSAligos Therapeutics2026-08-12 20:05 EST

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

ALGSAligos Therapeutics2026-08-12 20:05 EST

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Stock data

Close
5.50 USD
Market cap
32.49M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States